KWAN, MIN-FUN RUDOLF,关 鲁道夫,關 魯道夫,LAU, JOHNSON YIU-NAM,刘 耀南,劉 耀南,CHAN, WING KAI,陈荣楷,陳榮楷,SMOLINSKI, MICHAEL P.,史莫林斯基 麦可,史莫林斯基 麥可
申请号：
TW108113027
公开号：
TW202011955A
申请日:
2019.04.15
申请国别(地区):
TW
年份:
2020
代理人:
摘要：
The application pertains to pharmaceutical combinations of orally administered paclitaxel and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of an angiosarcoma in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered paclitaxel (e.g., Taxol® or paclitaxel formulated with Cremophor®) therapy in a subject suffering from an angiosarcoma.本案關於口服投予的紫杉醇和P-gp抑制劑的醫藥組合。該醫藥組合適用於治療個體中血管肉瘤，及用於減少或預防在患有血管肉瘤個體中由靜脈內投予紫杉醇(例如，Taxol®或用Cremophor®製劑的紫杉醇)療法產生或與靜脈內投予紫杉醇療法相關的毒性、過敏型輸注反應(hypersensitivity-type infusion reaction)及其他負面結果。
